Which Pharma Companies Are Dx Ready For Precision Medicine in 2017? Benchmarking, Financial Risks and Predictions | Diaceutics

Which Pharma Companies Are Dx Ready For Precision Medicine in 2017? Benchmarking, Financial Risks and Predictions

December 20th, 2016

Ewelina Golebiewska
Steve Vitale
Ryan Keeling

For the 2017 Pharma Readiness for Dx Index, Diaceutics applies analyses to 23 companies and examines the precision medicine (PM) credentials of over 1000 therapies on the market and in the pipeline, providing a 360° view of Dx-dependent therapy (Rx) assets. We include Big Data and lab partnerships alongside Rx/Dx partnerships to reflect the evolution of PM beyond molecular testing? and make considered predictions for the industry as it develops.

Listen to the webinar to learn:

  • What’s new in this year’s Pharma Readiness for Dx report
  • How the diagnostic market is currently placed and where it is heading in 2017 and beyond
  • How pharma readiness and financial risks can impact the industry

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications